Roger Pebody

Roger Pebody is the managing editor at NAM, a nonprofit organization in the United Kingdom that publishes news, information, and educational materials about HIV. He runs the day-to-day content operations at aidsmap, NAM's flagship site, for which he has worked since 2008.

Latest by Roger Pebody

U=U: What HIV Providers Should Know

Due to community pressure and activism, the language that physicians, scientists, and public health bodies use to describe the potential for HIV transmission when a person has an undetectable viral load is now much clearer.

By Roger Pebody

Four Models of PrEP Service Provision to Enhance Access and Uptake

The uptake of pre-exposure prophylaxis (PrEP) has been highly skewed, with some people who need PrEP the most being less likely to get it.

By Roger Pebody

HIV Tied to Greater Erectile Dysfunction Among Men Over 45

A Dutch cohort study of men who have sex with men (MSM) over the age of 45 finds that HIV infection and lopinavir/ritonavir use each are independently associated with decreased erectile function.

By Roger Pebody

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).

By Roger Pebody

Osteopenia: Zoledronic Acid Has Greater Impact Than Switching From Tenofovir Disoproxil Fumarate Regimens

For HIV-positive men with osteopenia, bisphosphonate therapy with zoledronic acid is more effective at increasing bone mineral density than switching from tenofovir disoproxil fumarate (TDF, Viread).

By Roger Pebody

Managing Risk Compensation in PrEP Users

PrEP remains an underutilized method of HIV prevention, with growing evidence that the most important barriers to wider use do not lie with patients but with health care professionals.

By Roger Pebody

Yes to PrEP: A Prescriber's Next Steps

Key next steps in providing PrEP are:

Discuss PrEP with your patient.

Ask what he or she is currently doing to protect themselves from HIV. Discuss the benefits and risks of PrEP.

Identify insurance or other reimbursement for your patient.


By Roger Pebody

HIV, Vaginal Sex and PrEP Initiation: What Should You Tell Your Patients or Clients?

There's a big difference between 7 days and 20 days. Listen in as researchers and providers hash out the data, and what to tell those who need the information the most.

By Roger Pebody

Less Than Half of People With HIV Who Are Eligible for Statins Receive Them

There is a significant "statin treatment gap" for people living with HIV, with only 47% of people eligible for statins receiving them in 2013, according to a recent study.

By Roger Pebody

ACA's Medicaid Expansion Significantly Increased Coverage and Clinical Outcomes for People With HIV

Due to the impact of the Affordable Care Act (ACA), in just two years the proportion of people living with HIV in care covered by Medicaid increased from 36% to 42% and the proportion that were uninsured fell from 18% to 14%.

By Roger Pebody